〔Abstract〕 Objectives To investigate the expression and clinical significance of TRIM32 in Cutaneous Malignant Melanoma patients. Methods Real-time PCR was used to detect the expression of TRIM32 in human melanoma cell lines(A375,MV3) and human normal skin cell lines(HACAT). Clinical characteristics of 31 CMM patients were collected. The expression of TRIM32 in the CMM tissues and para-cancerous tissues was detected by immunohistochemistry(IHC). The correlation between TRIM32 expression and clinical characteristics was analyzed. Kaplan-Meier survival analysis and Cox univariate analysis model were used to analyze the prognostic factors. Results The expression of TRIM32 mRNA in A375 melanoma cells was significantly higher than that in HACAT normal skin cells(P<0.001),while the expression in MV3 cells was comparable to that in HACAT cells. The expression of TRIM32 protein in the CMM tissues, detected by IHC, was significantly higher than that in the para-cancerous tissues(P<0.001) and positively correlated with Breslow thickness(r=0.771,P<0.001) and Clark grade(r=0.635,P<0.001), but not with sex, ulcer, age and primary location of tumor(P>0.05). Also, TRIM32 expression level was significantly correlated with prognosis of CMM. Conclusion TRIM32 is highly expressed in A375 melanoma cells and CMM tissues. TRIM32 may be helpful for the prognosis of CMM patients.